Published on 15 Mar 2024 on Zacks via Yahoo Finance
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
Allogene Therapeutics, Inc. ALLO incurred an adjusted loss (excluding impairment of long-lived asset) of 43 cents per share in fourth-quarter 2023, narrower than the Zacks Consensus Estimate of a loss of 47 cents.
Inclusive of impairment charges, the company posted a loss of 51 cents in the fourth quarter. In the year-ago quarter, the company reported a loss of 67 cents. There was no impairment charge recorded in the year-ago period.
ALLO recorded revenues of $0.02 million during the quarter, missing the Zacks Consensus Estimate of $0.05 million. Revenues were down 19% year over year.